To the Editor,
Patients with chronic lymphocytic leukemia (CLL) have an increased incidence of secondary malignancies, such as solid tumors and lymphoid malignancies, during their clinical course. Here, we report a case of synchronous detection of colon cancer during initial staging with whole-body positron emission tomography (PET) with fluorine-18 f luorodeoxyglucose ( 18 F-FDG) in a 53-year-old male patient with newly diagnosed CLL. Extranodal involvement and high-intensity FDG uptake in CLL are rare; thus, increased uptake in localized extranodal sites is highly suspicious of transformation to other hematological malignancies or the development of secondary solid tumors. Our f indings suggest that patients with CLL should be carefully evaluated for secondary cancers in the initial staging and during the follow-up period. 18 FDG-PET/computed tomography (CT) may be useful for detecting secondary malignancies; however, further studies are needed to investigate the cost-effectiveness of this imaging procedure compared to conventional CT in the follow-up setting.
A 53-year-old male presented with chronic fatigue, night sweats, constipation, and a weight loss of 4 kg experienced over a 3-month period. He was otherwise relatively well and asymptomatic and had no history of previous exposure to ionizing radiation, cytotoxic agents, or a family history of leukemia. Physical examination revealed no lymphadenopathy, but the spleen tip was palpable 8 cm below the left lower costal margin. The peripheral blood (PB) white cell count was 34.3 × 10 9 /L, with 70% lymphocytes. The complete blood count revealed a hemoglobin level of 11.0 g/dL and platelet count of 149 × 10 9 /L of blood. Bone marrow (BM) aspirate was hypercellular; 70% of cells were mature B-lymphocytes. Immunophenotyping of PB and BM revealed a monoclonal B-lymphocyte population expressing surface immunoglobulin (slg) kappa (κ), CD19, CD20, CD5, and CD23 antigens. However, cytogenetic analysis using f luorescence in situ hybridization showed no specific chromosomal abnormalities. rence of colon cancer was found. The surveillance PET/ CT scan and colonoscopy were unremarkable. At the time of writing, the patient had received a total of five cycles of fludarabine plus cyclophosphamide (FC) chemotherapy and is in complete remission without recurrence of colon cancer following the surgery. CLL and other malignant neoplasms occasionally occur concomitantly, and patients with CLL are at significantly increased risk of developing solid tumors such as lung cancer, gastrointestinal carcinoma, and melanoma (Supplementary Table 1 online). In a large study involving 4,869 patients with CLL diagnosed between 1935 and 1971, subsequent neoplasms were observed in 4.8% of cases, and the relative risk (RR) was estimated to be 1.1, with a 95% confidence interval (CI) of 1.0 to 1.3. The National Cancer Institute's Surveillance, Epidemiology, and End Results Cancer Statistics Review 1973 to 1996 reported subsequent neoplasms in 11.1% of CLL cases (RR, 1.20; 95% CI, 1.15 to 1.26). Both reports found significant excess risks of Kaposi's sarcoma (RR, 5.3 and 5.09, respectively) and malignant melanoma (RR, 6.7 and 3.18, respectively). However, the neoplasms most commonly identif ied as having an elevated RR were cancers of the lung (RR, 1.5 and 1.66, respectively) and colon (RR, 1.0 and 1.13, respectively).
Prolonged immunosuppression caused by asymptomatic B-cell CLL and chemotherapy, including the use of alkylating agents, may explain the association between CLL and secondary malignancies. That is, patients with CLL have an increased risk of developing additional malignancies during their clinical course, particularly when they have been treated with alkylating agents for long periods. Thus, clinicians should be aware of the potential for of a secondary malignancies occurring in patients with CLL [1] .
Secondary malignancies may be detected incidentally regardless of treatment regime, but they may be more frequent in patients with CLL exposed to nucleoside analog therapy [2] . The present case is notable because the synchronous colon cancer was detected during initial staging with whole body PET with 18 F-FDG in a patient with newly diagnosed CLL. PET imaging is useful for diagnosing hematological malignancies, particularly Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma, and is recommended for staging, prediction of prognosis, treatment planning, and response evaluation of lymphomas [3] CT has not provided useful information for the management of CLL with the exception of detecting Richter's transformation; thus, further studies should investigate the cost-effectiveness and benefit of PET/CT compared to conventional CT in the follow-up period [3, 4] . The prognosis for CLL with secondary malignancies is generally poor.
Here we present a case of synchronously diagnosed B-cell CLL and adenocarcinoma of the colon. Although previous studies have reported a nonsignificant increase in colon cancer subsequent to the diagnosis of CLL, we noted an epidemiological association in our case suggesting the neoplasm was not a simple coincidence. This synchronous relationship may be explained in terms of prolonged immunosuppression as a result of asymptomatic B-cell CLL or shared cancer genes. A common alteration on chromosome 7, which has been demonstrated in 10% to 15% of B-cell CLL and 75% of colorectal cancer patients, may be the genetic basis of an association between hematological malignancy and hereditary nonpolyposis colon cancer with abnormalities in p53 gene expression. Chemotherapy administered in early stage B-cell CLL does not provide a survival advantage over conservative treatment and does not reduce the incidence of second neoplasms. Furthermore, the risk of recurrent solid tumors with a diagnosis of B-cell CLL has not been investigated.
Here, we report an incidentally identified colon cancer in a 53-year-old male with newly diagnosed CLL during initial staging with whole body PET scanning with 18 F-FDG. Our patient achieved complete remission 2 months after three cycles of FC chemotherapy with no evidence of recurrent colon cancer or other malignancies following surgery. Patients with CLL have an in-
